259 related articles for article (PubMed ID: 30475204)
1. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
Elife; 2018 Nov; 7():. PubMed ID: 30475204
[TBL] [Abstract][Full Text] [Related]
2. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
4. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Unni AM; Lockwood WW; Zejnullahu K; Lee-Lin SQ; Varmus H
Elife; 2015 Jun; 4():e06907. PubMed ID: 26047463
[TBL] [Abstract][Full Text] [Related]
5. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
Zhang Z; Kobayashi S; Borczuk AC; Leidner RS; Laframboise T; Levine AD; Halmos B
Carcinogenesis; 2010 Apr; 31(4):577-86. PubMed ID: 20097731
[TBL] [Abstract][Full Text] [Related]
6. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
[TBL] [Abstract][Full Text] [Related]
8. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of dual-specificity phosphatase 6, a negative regulator of oncogenic ERK signaling, by ACA-28 induces apoptosis in NIH/3T3 cells overexpressing HER2/ErbB2.
Kanda Y; Mizuno A; Takasaki T; Satoh R; Hagihara K; Masuko T; Endo Y; Tanabe G; Sugiura R
Genes Cells; 2021 Feb; 26(2):109-116. PubMed ID: 33249692
[TBL] [Abstract][Full Text] [Related]
10. NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity.
Ingram K; Samson SC; Zewdu R; Zitnay RG; Snyder EL; Mendoza MC
Oncogene; 2022 Jan; 41(2):293-300. PubMed ID: 34689179
[TBL] [Abstract][Full Text] [Related]
11. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
12. Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Moncho-Amor V; Pintado-Berninches L; Ibañez de Cáceres I; Martín-Villar E; Quintanilla M; Chakravarty P; Cortes-Sempere M; Fernández-Varas B; Rodriguez-Antolín C; de Castro J; Sastre L; Perona R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027181
[TBL] [Abstract][Full Text] [Related]
13. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
14. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
Ambrogio C; Barbacid M; Santamaría D
Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
[TBL] [Abstract][Full Text] [Related]
15. How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?
Varmus H; Unni AM; Lockwood WW
Cold Spring Harb Symp Quant Biol; 2016; 81():247-255. PubMed ID: 28123049
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
17. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
18. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
19. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity.
Huang W; Ray P; Ji W; Wang Z; Nancarrow D; Chen G; Galbán S; Lawrence TS; Beer DG; Rehemtulla A; Ramnath N; Ray D
J Biol Chem; 2020 May; 295(18):5906-5917. PubMed ID: 32165494
[TBL] [Abstract][Full Text] [Related]
20. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
